2026年1月9日,中国创新药领域迎来里程碑事件——小核酸药物龙头企业瑞博生物以每股57.97港元正式登陆资本市场。当天,开盘即大涨,收盘价为每股82.1港元,较发行价大涨41.6%,市值约136.1亿港元。本次IPO不仅是一家企业的胜利,更是中国在小核酸制药这个“第三次药物革命”浪潮中实现的重要突破。背后站着的,是中国小核酸产业的奠基人梁子才教授。这位将siRNA技术首次引入中国并命名为“小核酸...
Source Link2026年1月9日,中国创新药领域迎来里程碑事件——小核酸药物龙头企业瑞博生物以每股57.97港元正式登陆资本市场。当天,开盘即大涨,收盘价为每股82.1港元,较发行价大涨41.6%,市值约136.1亿港元。本次IPO不仅是一家企业的胜利,更是中国在小核酸制药这个“第三次药物革命”浪潮中实现的重要突破。背后站着的,是中国小核酸产业的奠基人梁子才教授。这位将siRNA技术首次引入中国并命名为“小核酸...
Source LinkDisclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.